Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-114801 · Präparat HOS-094169
Metabolic profile of tipranavir Tipranavir is a substrate, an inducer and an inhibitor of cytochrome P450 CYP3A. When co- administered with ritonavir at the recommended dosage (see section 4.2) there is a net inhibition of P450 CYP3A. Co-administration of Aptivus and low dose ritonavir with agents primarily metabolised by CYP3A may result in changed plasma concentrations of tipranavir or the other agents, which could alter their therapeutic and undesirable effects (see list and details of considered agents, below). Agents that are contraindicated specifically due to the expected magnitude of interaction and potential for serious adverse reactions are detailed in this section, and listed in section 4.3.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 30ad3d2cb57069822514f4fd39c33c6f2a601812f4dcd9c0f5bfe89c63247c05 · Zeichen 240–951 im Abschnitt